
Afya grabbed headlines this year when it moved from early stage talks to a signed merger agreement with Yduqs, a plan that would fold Afya into a larger higher education group listed on Brazil’s B3. If you had decided to back that story at the very start of 2026, the ride has been rough. Holding Afya from the start of the year would have meant a 27.9% loss, including dividends. The real question now is whether the proposed Yduqs combination genuinely reshapes Afya’s long term appeal or instead complicates an already difficult investment story.
Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.
This theme extends beyond Afya. See which of 36 healthcare AI stocks may still merit a closer look.
The shares cost US$15.41 at the start of the period, so anyone looking at Afya then had to decide which story felt more realistic.
The bullish narrative saw Fair Value at US$19.7, implying that expanding medical seats and digital services could support revenue growth and higher EBITDA margins from operating leverage.
The bearish view put Fair Value at US$14.09 and focused on AI driven online rivals in medical training as a potential challenge for Afya’s campus model and future tuition pricing power.
The binding merger agreement with Yduqs turned Afya’s consolidation story into a concrete transaction that clearly backed the bullish case around scale and medical education focus. At the same time, Q3 2026 numbers showed revenue up to R$985.2m and net income at R$166.3m with a slightly higher 16.9% margin, which supported profitability but did not settle the digital or AI risk. Overall, the evidence cut both ways.
The lesson here is simple. When a thesis hangs on scale and resilience, treat each merger step and each reported net margin as separate checkpoints, and test both against the original assumptions before updating your view on any education stock.
Afya now trades at US$10.32, after a year to date loss of 27.9% from the start of the year. The bullish analyst Narrative on Simply Wall St sees Fair Value above that level, tied to how the planned Yduqs merger and Afya’s health education footprint might work together.
Rather than treat the fall as a clear warning, a buyer today would need to believe Afya and Yduqs can actually deliver the merger synergies and AI upgrades described in that Narrative. The key test is whether those execution gains can outweigh pressure from cheaper digital rivals and regulatory change.
"Bullish analysts expect Afya to use the planned merger with Yduqs, the expansion in medical and broader health education and the cash generation seen in H1 2026 to support continued growth in revenue, EBITDA and free cash flow for the combined group. The main thing that has to go right is that Afya and Yduqs actually capture the projected BRL 2.0 to 2.2b in net synergies and execute on AI driven upgrades across physician solutions while managing tax and regulatory changes around medical education and Pillar Two."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Afya’s story centers on regulated health degrees. Your attention naturally goes there first.
Look one step away and you find a different education engine. This other platform turns learning into a daily mobile habit for a global audience.
Instead of medical training, it focuses on languages and basic skills. Short sessions, game mechanics and a sticky free tier keep people returning.
That grip on user time matters. As more education shifts onto phones, a business already capturing those minutes could face interesting strategic choices.
That argument has a Narrative and a number behind it. → See the company one Narrative values 63% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com